Hemodynamics and Phosphodiesterase-5 Inhibitor Treatment Associated with Survival in Pulmonary Hypertension in Interstitial Lung Disease A PVRI GoDeep Meta-Registry Analysis
Research output: Contribution to journal › Research article › Contributed › peer-review
Contributors
- Department of Internal Medicine I
- Institute of Clinical Pharmacology
- Justus Liebig University Giessen
- Institute of Lung Health (ILH)
- Johns Hopkins Medicine
- Cleveland Clinic Abu Dhabi
- University of Sheffield
- Imperial College London
- University of Minnesota System
- Heidelberg University
- LKH Medical University Clinic Graz
- Mayo Clinic Rochester, MN
- Stanford University
- Aristotle University of Thessaloniki
- University of Cincinnati
- SLK-Kliniken Heilbronn GmbH
- Hannover Medical School (MHH)
- University of Regensburg
- Clinic Würzburg Mitte gGmbH
- University Hospital Carl Gustav Carus Dresden
- University of Greifswald
- Ludwig Maximilian University of Munich
- GWT-TUD GmbH
- Institute of Clinical Pharmacology
- RWTH Aachen University
- University of Pittsburgh
- Vanderbilt University Medical Center
- Evagelismos Hospital
- Kokilaben Dhirubhai Ambani Hospital & Medical Research Institute
- Royal Papworth Hospital NHS Foundation Trust
- University of Córdoba
- Universidad Nacional de La Plata
Abstract
Rationale: Pulmonary hypertension (PH) in interstitial lung disease (ILD) lacks approved therapies. Objectives: The Pulmonary Vascular Research Institute GoDeep metaregistry collects real-world data of patients with PH from international PH referral centers. Methods: Patients with ILD-PH and relevant subgroups (idiopathic interstitial pneumonia [IIP], idiopathic pulmonary fibrosis [IPF]) were stratified by pulmonary vascular resistance (PVR). Kaplan-Meier survival analyses and adjusted Cox proportional hazards models were employed, additionally accounting for immortal time bias, sensitivity analyses, Heller explained relative risk statistics, and target trial emulation framework analysis. Measurements and Main Results: Among 34,482 patients, 940 with hemodynamically fully characterized incident ILD-PH (median age, 67 [IQR, 59–74] yr) were identified. A total of 62% had severe ILD-PH with PVR .5 Wood units (WU) and poor survival rates (29% and 18% at 3 and 5 yr), significantly worse than patients with ILD-PH with PVR <5 WU and patients with pulmonary arterial hypertension. Survival was poorest in severe IPF-PH. A total of 59% of all patients ILD-PH received PH-targeted therapy, predominantly phosphodiesterase-5 inhibitors (PDE5is). PDE5i treatment was consistently associated with significantly improved survival in patients with severe PH (hazard ratios of 0.537 [0.370–0.781], 0.461 [0.233–0.913], and 0.435 [0.215–0.8] for IIP-PH, IPF-PH, and IIP-PH with nintedanib/pirfenidone background therapy), but not in patients with less severe hemodynamic impairment, supported by sensitivity analyses, Heller statistics, and target trial emulation framework analysis. The survival statistics of patients with PDE5i-treated IIP-PH or IPF-PH were validated in the independent COMPERA registry. Combination therapy with PDE5is and inhaled prostacyclin analogues was superior to monotherapy using PDE5is (hazard ratio, 0.341; 0.205–0.566). Conclusions: Prognosis in ILD-PH was generally very poor and was related to PH severity. PDE5i treatment in severe IIP-PH and IPF-PH was associated with improved survival, which is to be further verified in controlled trials.
Details
| Original language | English |
|---|---|
| Pages (from-to) | 1855-1866 |
| Number of pages | 12 |
| Journal | American journal of respiratory and critical care medicine |
| Volume | 211 |
| Issue number | 10 |
| Publication status | Published - Oct 2025 |
| Peer-reviewed | Yes |
External IDs
| PubMed | 40772955 |
|---|
Keywords
ASJC Scopus subject areas
Keywords
- interstitial lung disease, pulmonary hypertension, PVRI GoDeep, treatment